▲ +6.12% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Zymeworks in the last 3 months. The average price target is $52.91, with a high forecast of $70.00 and a low forecast of $42.00. The average price target represents a 6.12% upside from the last price of $49.86.
The current consensus among 11 investment analysts is to buy stock in Zymeworks. This Buy consensus rating has held steady for over two years.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; collaboration with Applied BioMath, LLC.; and a research collaboration with ImmunoPrecise Antibodies Ltd. for the development of multiple antibody candidates to fight COVID-19. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.